Vertex Pharmaceuticals Incorporated announced its Supplement to a New Drug Submission for PrKALYDECO® (ivacaftor) has been accepted for priority review by Health Canada for the treatment of cystic fibrosis (CF) in patients from 4 months to 18 years of age and weighing at least 5 kg with the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.